Answers are grounded in this paper and cite their sources.
The findings of this study have important implications for drug development. The lack of a clear dose-response relationship, due to large pharmacokinetic variability, indicates that a one-size-fits-all approach to CBD dosing may not be feasible, at least with current dosing approaches. Furthermore, an extended time to reach steady state means that the full effect of a selected dose level is not truly observed for some time and requires careful consideration in trial design.
No takes yet. Share an insight, caveat, or question.
Schultz et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: